770 related articles for article (PubMed ID: 17916095)
21. [Cell-block immunocytochemical characterization of effusions. Use of antibody panel: calretinin, Ber-EP4, keratin and CD68].
Lucchi I; Morigi F; Naldi S; Tabarri B; Elegibili E; Giangaspero F
Pathologica; 1999 Dec; 91(6):447-52. PubMed ID: 10783640
[TBL] [Abstract][Full Text] [Related]
22. Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology.
Kundu UR; Krishnamurthy S
Cancer Cytopathol; 2011 Aug; 119(4):272-8. PubMed ID: 21732548
[TBL] [Abstract][Full Text] [Related]
23. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
Ciampa A; Fanger G; Khan A; Rock KL; Xu B
Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
[TBL] [Abstract][Full Text] [Related]
24. Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice.
Mohammad T; Garratt J; Torlakovic E; Gilks B; Churg A
Am J Surg Pathol; 2012 Oct; 36(10):1503-8. PubMed ID: 22982894
[TBL] [Abstract][Full Text] [Related]
25. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
Delahaye M; Hoogsteden HC; Van der Kwast TH
J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
[TBL] [Abstract][Full Text] [Related]
26. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
Pu RT; Pang Y; Michael CW
Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
[TBL] [Abstract][Full Text] [Related]
27. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases.
Chu PG; Weiss LM
Mod Pathol; 2002 Jan; 15(1):6-10. PubMed ID: 11796835
[TBL] [Abstract][Full Text] [Related]
28. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
[TBL] [Abstract][Full Text] [Related]
29. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
30. Primary peritoneal mesotheliomas in children: a clinicopathological and immunohistochemical study of eight cases.
Moran CA; Albores-Saavedra J; Suster S
Histopathology; 2008 Jun; 52(7):824-30. PubMed ID: 18494612
[TBL] [Abstract][Full Text] [Related]
31. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
[TBL] [Abstract][Full Text] [Related]
33. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
[TBL] [Abstract][Full Text] [Related]
34. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
35. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
36. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
37. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
Ordóñez NG
Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
[TBL] [Abstract][Full Text] [Related]
38. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
Kobzik L; Antman KH; Warhol MJ
Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
[TBL] [Abstract][Full Text] [Related]
39. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
[TBL] [Abstract][Full Text] [Related]
40. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
Conner JR; Cibas ES; Hornick JL; Qian X
Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]